Bcr abl qualitative pcr on blood at Dr. Essa Lab

Bcr abl qualitative pcr on blood at Dr. Essa Lab

The Bcr abl qualitative pcr on blood at Dr. Essa Lab is a highly specialized molecular diagnostic test designed to detect the presence of the BCR-ABL fusion gene. This abnormal gene is the hallmark of the Philadelphia chromosome, a genetic translocation associated with specific types of leukemia, most notably Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL). By utilizing advanced Polymerase Chain Reaction (PCR) technology, this test identifies the specific genetic sequence resulting from the reciprocal translocation between chromosomes 9 and 22. This translocation fuses the ABL1 gene from chromosome 9 with the BCR gene on chromosome 22, creating an oncogene that produces an abnormal tyrosine kinase protein. This protein drives the uncontrolled proliferation of white blood cells, leading to leukemia.

At Dr. Essa Lab, a premier diagnostic institution in Pakistan, this molecular test is performed with the highest standards of clinical precision. The qualitative PCR assay is designed to provide a definitive ‘Detected’ or ‘Not Detected’ result, which is crucial for the initial diagnosis, classification, and clinical management of patients presenting with symptoms of hematological malignancies. Understanding the molecular basis of leukemia through this test allows hematologists and oncologists to design targeted therapeutic strategies, particularly involving Tyrosine Kinase Inhibitors (TKIs) such as imatinib, nilotinib, and dasatinib. The test evaluates peripheral blood samples, eliminating the immediate need for invasive bone marrow biopsies in preliminary screening phases, thereby offering a patient-friendly yet highly sensitive diagnostic pathway.

The clinical importance of the Bcr abl qualitative pcr on blood cannot be overstated. It serves as the diagnostic cornerstone for differentiating CML from other myeloproliferative neoplasms and reactive leukocytosis. The diagnostic value lies in its exceptional sensitivity and specificity; it can detect the fusion transcript even when present in minute quantities among millions of normal cells. This makes it an invaluable tool not only for primary diagnosis but also for assessing minimal residual disease (MRD) and monitoring patients for potential relapse. By choosing Dr. Essa Lab, patients benefit from state-of-the-art molecular pathology infrastructure, expert interpretation by qualified clinical pathologists, and a commitment to delivering accurate, timely, and actionable diagnostic insights.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is essential to ensure the integrity of the blood sample and the accuracy of the molecular analysis. Patients undergoing the Bcr abl qualitative pcr on blood at Dr. Essa Lab should follow these guidelines:

• No Fasting Required: Unlike routine biochemistry tests, fasting is not mandatory for this molecular assay. Patients may eat and drink normally before the procedure.
• Medication History: Inform the healthcare provider and laboratory staff about all current medications, especially chemotherapy agents, immunosuppressants, or Tyrosine Kinase Inhibitors (TKIs), as these can influence clinical interpretation.
• Clinical Documentation: Bring all relevant medical records, previous hemograms (Complete Blood Count reports), and referral letters from the consulting hematologist.
• Hydration: Remain well-hydrated before the blood draw, as this makes the veins more accessible and facilitates a smoother venipuncture process.
• Clothing: Wear comfortable clothing with sleeves that can be easily rolled up above the elbow.

During the Procedure

The collection of the blood sample for the Bcr abl qualitative pcr on blood is a standard venipuncture procedure conducted under strict aseptic conditions. Here is what to expect during the process at Dr. Essa Lab:

• Patient Identification and Verification: The phlebotomist will verify the patient’s identity using official identification and the test requisition form to ensure absolute traceability.
• Positioning: The patient will be seated comfortably in a specialized phlebotomy chair, with their arm extended and supported.
• Site Selection and Sanitization: The phlebotomist will locate a suitable vein, typically the median cubital vein in the antecubital fossa (inner elbow). The skin over the selected vein is thoroughly cleansed with an antiseptic solution (such as 70% isopropyl alcohol) and allowed to air dry to prevent contamination.
• Tourniquet Application: A sterile tourniquet is applied a few inches above the selected site to transiently restrict venous flow, making the vein more prominent and easier to access.
• Venipuncture: Using a sterile, single-use needle attached to a vacuum collection tube (specifically an EDTA tube, usually with a lavender top), the phlebotomist gently inserts the needle into the vein. Patients may feel a brief, mild pinch or prick.
• Sample Collection: The required volume of blood (typically 3 to 5 mL) is drawn into the tube. The EDTA anticoagulant prevents clotting, preserving the cellular integrity and the RNA required for molecular extraction.
• Needle Removal and Hemostasis: The tourniquet is released, the needle is gently withdrawn, and immediate pressure is applied to the puncture site with a sterile cotton ball or gauze pad to prevent hematoma formation. A small adhesive bandage is then applied.
• Sample Processing: The tube is gently inverted several times to mix the blood thoroughly with the anticoagulant. It is immediately labeled with the patient’s unique barcode and prepared for transport to the molecular pathology division under controlled temperature conditions.

When is a Bcr abl qualitative pcr on blood Performed?

Diagnosis of Chronic Myeloid Leukemia (CML)

Physicians request this test when a patient presents with clinical signs, symptoms, or routine laboratory findings suggestive of Chronic Myeloid Leukemia. CML is characterized by a massive overproduction of granulocytes. The qualitative PCR test is performed to confirm the presence of the t(9;22) translocation, which is the defining genetic marker found in more than 95% of CML cases. Confirming this molecular signature is essential for establishing a definitive diagnosis and initiating targeted therapy.

Evaluation of Acute Lymphoblastic Leukemia (ALL)

In patients diagnosed with Acute Lymphoblastic Leukemia, particularly adults, determining the Philadelphia chromosome status is critical. Approximately 20% to 30% of adult ALL cases are Philadelphia chromosome-positive (Ph+ ALL). The presence of the BCR-ABL fusion gene in ALL patients alters the prognostic outlook and dictates the inclusion of tyrosine kinase inhibitors in the chemotherapy regimen. The qualitative PCR test helps clinicians rapidly identify this high-risk subset of patients.

Monitoring Minimal Residual Disease (MRD)

Following chemotherapy, bone marrow transplantation, or targeted TKI therapy, patients may achieve clinical and hematological remission, where abnormal cells are no longer visible under a microscope. However, subclinical levels of leukemia cells may persist. The Bcr abl qualitative pcr on blood is performed to detect minimal residual disease (MRD). Its high sensitivity allows it to identify the presence of the fusion transcript at molecular levels, helping clinicians detect early signs of potential relapse.

Assessing Therapeutic Response to Tyrosine Kinase Inhibitors (TKIs)

For patients undergoing treatment with TKIs, monitoring the genetic marker is essential to evaluate the efficacy of the therapy. A qualitative test can confirm whether the patient has achieved a complete molecular response, defined as the complete absence of detectable BCR-ABL fusion transcripts in the blood. If the test remains positive or switches from negative to positive, it may indicate treatment failure, poor compliance, or the development of drug-resistant mutations, prompting further quantitative and mutational analysis.

Investigating Unexplained Leukocytosis or Thrombocytosis

When routine blood tests reveal persistently elevated white blood cell counts (leukocytosis) or abnormally high platelet counts (thrombocytosis) without an obvious infectious or inflammatory cause, clinicians must rule out myeloproliferative neoplasms. The Bcr abl qualitative pcr on blood is used as a primary screening tool to differentiate clonal hematological disorders like CML from reactive conditions or other BCR-ABL-negative myeloproliferative disorders such as Essential Thrombocythemia or Polycythemia Vera.

What Does a Bcr abl qualitative pcr on blood Detect?

The Bcr abl qualitative pcr on blood is designed to detect specific molecular, genetic, and clinical parameters associated with the t(9;22) translocation. The test specifically identifies and evaluates:

• The presence of the BCR-ABL1 fusion hybrid gene in peripheral blood cells.
• The reciprocal translocation between the long arms of chromosomes 9 and 22 [t(9;22)(q34.1;q11.2)].
• The major breakpoint cluster region (M-bcr) transcripts, which typically produce the p210 fusion protein (common in CML).
• The minor breakpoint cluster region (m-bcr) transcripts, which produce the p190 fusion protein (frequently associated with Ph+ ALL).
• The micro breakpoint cluster region (μ-bcr) transcripts, which produce the p230 fusion protein (associated with rare neutrophilic leukemia).
• The presence of the Philadelphia (Ph) chromosome at a molecular level.
• The adequacy of the extracted ribonucleic acid (RNA) from the patient’s white blood cells.
• The amplification of internal control genes (such as ABL1 or GUSB) to ensure the PCR reaction was successful and free of inhibitors.
• The qualitative molecular status of the patient (either ‘Detected’ or ‘Not Detected’).
• Minimal residual disease (MRD) in post-treatment surveillance.
• Early molecular relapse before clinical symptoms manifest.
• The molecular response to targeted tyrosine kinase inhibitor (TKI) therapies.
• Clonal persistence in patients undergoing bone marrow or stem cell transplantation.
• The genetic basis of unexplained, extreme leukocytosis.
• The genetic basis of unexplained thrombocytosis.
• The differentiation between CML and leukemoid reactions (reactive white blood cell elevation).
• The differentiation between CML and other BCR-ABL-negative myeloproliferative neoplasms.
• The presence of atypical fusion transcripts that may require specialized primer designs.
• The suitability of the patient for targeted therapeutic protocols.
• The baseline molecular status prior to the initiation of any cytoreductive therapy.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Lab, the processing of molecular diagnostic tests like the Bcr abl qualitative pcr on blood is handled with the utmost urgency and precision. Because molecular assays involve complex steps—including RNA extraction, reverse transcription to complementary DNA (cDNA), PCR amplification, and post-amplification analysis—the turnaround time is typically within 3 to 5 working days. This timeline ensures that every sample undergoes rigorous quality control protocols to eliminate the possibility of false positives or false negatives.

Patients and referring physicians can easily access diagnostic reports through Dr. Essa Lab’s secure digital portal. Once the clinical pathologist signs off on the results, an automated SMS notification is sent to the patient’s registered mobile number. Reports can be viewed, downloaded, and printed directly from the official website or via the dedicated mobile application. Physical copies of the reports are also available for collection at any of the convenient Dr. Essa Lab diagnostic centers located across Karachi and other major cities in Pakistan.

Bcr abl qualitative pcr on blood Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
BCR-ABL1 Fusion Transcript	Not Detected (Negative)	Detected (Positive)
Transcript Variant Type	Not Applicable	p210 (CML), p190 (ALL), or p230 (Neutrophilic Leukemia) detected
Internal Control Gene (e.g., ABL1)	Adequate amplification (Validates test)	Inadequate amplification (Invalid run, sample degraded)
Philadelphia Chromosome Status	Negative	Positive (Molecular evidence of t(9;22))
Molecular Remission Status	Complete Molecular Response (in known patients)	Persistent or recurrent molecular disease
RNA Quality and Integrity	High-quality RNA extracted	Degraded RNA (requires fresh sample collection)
Clinical Interpretation	No molecular evidence of BCR-ABL1 leukemia	Consistent with CML, Ph+ ALL, or Ph+ AML

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Bcr abl qualitative pcr on blood?

• Experienced healthcare professionals: Our molecular pathology division is staffed by highly trained molecular biologists and consultant clinical pathologists who specialize in hematological malignancies.
• Patient-focused care: We prioritize patient comfort, safety, and clear communication throughout the testing process, ensuring a stress-free experience.
• Quality diagnostic services: Dr. Essa Lab adheres to stringent international quality control standards, ensuring the highest level of accuracy for molecular genetic testing.
• Professional reporting: Our reports are comprehensive, clear, and designed to provide clinicians with the precise molecular details needed for treatment planning.
• Modern diagnostic approach: We utilize advanced real-time PCR platforms and state-of-the-art thermal cyclers to deliver highly sensitive and specific results.
• Comfortable environment: All our collection centers are designed to meet high standards of hygiene, patient comfort, and professional clinical care.
• Convenient location: With an extensive network of branches across Karachi and other regions, patients can easily access our diagnostic services close to home.
• Commitment to accurate diagnosis: We understand the critical nature of leukemia diagnostics and are dedicated to providing rapid, reliable, and clinically validated results to guide timely medical intervention.